Aurinia Pharma Files 2025 DEF 14A
Ticker: AUPH · Form: DEF 14A · Filed: Apr 17, 2025 · CIK: 1600620
| Field | Detail |
|---|---|
| Company | Aurinia Pharmaceuticals Inc. (AUPH) |
| Form Type | DEF 14A |
| Filed Date | Apr 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
TL;DR
Aurinia Pharma's 2025 DEF 14A is out, detailing exec pay & equity awards for 2020-2024.
AI Summary
Aurinia Pharmaceuticals Inc. filed its DEF 14A on April 17, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate governance matters. Key financial periods reported include fiscal years 2020 through 2024, with specific attention to equity awards and their adjustments.
Why It Matters
This filing provides crucial insights into how Aurinia Pharmaceuticals compensates its top executives, which can influence investor perception and company strategy.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) that primarily discloses executive compensation and corporate governance information, not material operational or financial changes.
Key Numbers
- 2020-2024 — Fiscal Years Reported (Covers compensation and equity award data over a five-year period.)
Key Players & Entities
- Aurinia Pharmaceuticals Inc. (company) — Filer of the DEF 14A
- 20250417 (date) — Filing date
- 20250515 (date) — Period of report
- 2024-12-31 (date) — Fiscal year end
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is used to solicit shareholder votes on important corporate matters, typically including the election of directors and executive compensation.
When was this specific DEF 14A filed by Aurinia Pharmaceuticals Inc.?
This DEF 14A filing was made on April 17, 2025.
What fiscal period does this DEF 14A cover?
The filing pertains to the period of report ending May 15, 2025, and includes financial data for fiscal years up to December 31, 2024.
What type of data is highlighted in the filing regarding the fiscal years 2020-2024?
The filing highlights data related to equity awards, including those in summary compensation tables and adjustments excluding values reported in those tables, for executive personnel (PeoMember).
Where is Aurinia Pharmaceuticals Inc. headquartered?
Aurinia Pharmaceuticals Inc. is located in Edmonton, Alberta, Canada, with its business and mailing addresses listed at #140, 14315 - 118 Avenue, Edmonton, A0, T5L 4S6.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 17, 2025 regarding Aurinia Pharmaceuticals Inc. (AUPH).